Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Johnson and Johnson
Federal Trade Commission
Dow
Merck
Moodys
Cantor Fitzgerald
Accenture

Generated: November 16, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206141

« Back to Dashboard

NDA 206141 describes MEROPENEM, which is a drug marketed by Acs Dobfar, Acs Dobfar Spa, Amneal Pharms, Aurobindo Pharma Ltd, Daewoong Pharm Co, Gland Pharma Ltd, Hospira Inc, Sandoz, Savior Lifetec Corp, and B Braun Medical Inc, and is included in ten NDAs. It is available from ten suppliers. Additional details are available on the MEROPENEM profile page.

The generic ingredient in MEROPENEM is meropenem. There are thirty-two drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the meropenem profile page.
Summary for 206141
Tradename:MEROPENEM
Applicant:Gland Pharma Ltd
Ingredient:meropenem
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 206141
Ingredient-typeCarbapenems
Suppliers and Packaging for NDA: 206141
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MEROPENEM meropenem INJECTABLE;INJECTION 206141 ANDA Gland Pharma Limited 68083-146 68083-146-10 10 VIAL in 1 CARTON (68083-146-10) > 20 mL in 1 VIAL
MEROPENEM meropenem INJECTABLE;INJECTION 206141 ANDA Gland Pharma Limited 68083-147 68083-147-10 10 VIAL in 1 CARTON (68083-147-10) > 30 mL in 1 VIAL

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength500MG/VIAL
Approval Date:Jun 8, 2016TE:APRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength1GM/VIAL
Approval Date:Jun 8, 2016TE:APRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Fuji
Argus Health
Harvard Business School
Healthtrust
Dow
Daiichi Sankyo
Cipla
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.